The Catholic University of Croatia, led by the Digit-HeaL team and Assistant Professor Čartolovni, hosted the plenary meeting of the PARADISE project on October 23rd and 24th. The PARADISE project (PersonAlisation of RelApse risk in autoimmune DISEase) brings together partners across Europe as part of the ERA PerMed Joint translational call for proposals (2022) for “Prevention in personalised Medicine”.

At the meeting in Zagreb participated partners from KTH Royal Institute of Technology (Sweden), the University of Freiburg (Germany), Firalis S.A. (France), The European Institute for Innovation through Health Data I-HD (Belgium), Vasculitis Ireland Awareness (Ireland), and the Bellvitge Biomedical Research Institute (Spain), led by the project coordinator Prof. Dr. Mark Little from the Trinity Translational Medicine Institute and the ADAPT Center at Trinity College Dublin.

On the first day of the meeting, the Vice-Rector for Science, Prof. Dr. Roberto Antolović, welcomed the participants on the University’s behalf, emphasizing the project’s importance and the University’s pride in being one of the partners. Over the two days of the meeting, participants presented their past work in the project and discussed future activities. Anto Čartolovni, head of the Digital healthcare ethics laboratory (Digit-HeaL) and Assistant Professor at the Faculty of Medicine of the Catholic University of Croatia, presented the work of his research group within PARADISE and also outlined the direction of their future activities.

Between meetings, participants had the opportunity to explore Zagreb and its history. At the end of the session, they expressed their satisfaction with the organization and hospitality the Catholic University of Croatia provided.

For more information about the PARADISE project, visit the official website or social media platforms (Twitter and LinkedIn).